Skin Cancer

The AJMC® Skin Cancer compendium is a comprehensive resource for clinical news and expert insights about melanoma and other skin cancers.

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma.  | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

skin cancer screening doctor - Seventyfour - stock.adobe.com
Global Skin Cancer Burden Among Older Adults Surged Since 1990, Driven by Keratinocyte Cancer

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com
Novel, Noninvasive Skin Cancer Detection Method Shows Promise

May 18th 2025

Dr. Jason Luke leads a panel discussing immunotherapy advances in Cutaneous and Basal Cell Carcinoma

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo